The role of autologous stem cell transplantation in adult patients with acute myeloid leukaemia (AML) in first remission is unclear, yet it has become standard treatment for myeloma and this paper explores whether the source of transplanted stem cells may explain this paradox. In total, 57 patients from the Royal Marsden Hospital who received an unpurged bone marrow transplant (ABMT) were matched with 114 patients from the EBMT registry who had undergone peripheral blood stem cell transplantation (PBSCT). Patients were matched for karyotype, FAB type, remission-autograft interval and age. In the PBSCT group, haematopoietic recovery was significantly faster and nonrelapse mortality at 4 years was significantly lower (13 vs 1%, P ¼ 0.04). The relapse rate and overall survival at 4 years (20 vs 31% and 77 vs 63%) were also better with PBSCT, although the differences were not statistically significant. Autografting should be reassessed in a randomised trial for first remission AML patients using peripheral blood as a source of stem cells rather than bone marrow.
Summary:
The role of autologous stem cell transplantation in adult patients with acute myeloid leukaemia (AML) in first remission is unclear, yet it has become standard treatment for myeloma and this paper explores whether the source of transplanted stem cells may explain this paradox. In total, 57 patients from the Royal Marsden Hospital who received an unpurged bone marrow transplant (ABMT) were matched with 114 patients from the EBMT registry who had undergone peripheral blood stem cell transplantation (PBSCT). Patients were matched for karyotype, FAB type, remission-autograft interval and age. In the PBSCT group, haematopoietic recovery was significantly faster and nonrelapse mortality at 4 years was significantly lower (13 vs 1%, P ¼ 0.04). The relapse rate and overall survival at 4 years (20 vs 31% and 77 vs 63%) were also better with PBSCT, although the differences were not statistically significant. Autografting should be reassessed in a randomised trial for first remission AML patients using peripheral blood as a source of stem cells rather than bone marrow. Autologous bone marrow stem cell transplatation (ABMT) after high dose chemotherapy as consolidation for acute myeloid leukaemia (AML) in first remission has been shown to have only marginal benefit in two decisive trials in the UK and US, [1] [2] [3] and thus autografting has been excluded as a treatment option in the latest MRC AML 15 UK National trial. Central to this decision was that benefit from the markedly reduced relapse rate following autografting was in part offset by a high transplant-related mortality (TRM; 12-14%), an inevitable consequence of using bone marrow (BM) (with purging in the US study), rather than peripheral blood stem cells (PBSC).
Before abandoning autotransplantation for AML, it is worth remembering that there were worries in these two studies about recruitment bias against patient entry into the autograft arms, 2,3 and relatively low numbers of patients actually received the treatment compared with the other treatment options (66 and 54%). There are also several additional recent observations that make it reasonable that we should re-explore autografting for AML using PBSC as the source of stem cells with its much lower TRM; these have tipped the balance in favour of making autografting (with PBSC) standard treatment for myeloma (MRC Myeloma VII trial). 4 In addition, it is clear that in myeloma, autografting works best after optimal prior therapy, 5 but in the two pivotal AML studies this pretransplant variable was not optimised, in one there was no consolidation, 2 in the other the BM was harvested before the final consolidation course. 3 Slow haematological recovery is a hallmark of ABMT in AML 6 and contributes to TRM. Delayed engraftment and TRM may be overcome with the use of PBSCs. However, based on limited clinical data, there is concern over higher relapse rates following PBSCT in AML. 7, 8 Unfortunately, at present there is not enough evidence to persuade investigators to go straight into another randomised trial of comparing BM with PBSC in first CR AML patients, because in the only previous study comparing these, the results were inconclusive. 9 We have therefore designed this present matched pair study to see if PBSC (EBMT Registry data) is superior to BM (Royal Marsden data) -the latter study having the most intensive pre-autograft consolidation chemotherapy published. 10 Such information might be enough to make investigators reconsider whether we should conduct a new prospective trial of autotransplantation to see if this could still have a place in the management of AML.
Patients and methods

Patients
From the prospectively maintained database 11 of the Leukaemia Unit at the Royal Marsden Hospital, we identified 57 unselected, consecutive patients with a diagnosis of primary AML who received an autograft with unpurged BM while in first complete remission. They were matched in a 1 : 2 ratio with 114 AML patients from the EBMT registry who received autologous PBSCT as consolidation therapy. 
Selection of matches
Treatment programmes
For RMH patients, the induction and early consolidation chemotherapy of the ABMT patients was given according to MRC AML 3 protocols (n ¼ 20) or as previously described [BF12 in 30, BF9 in seven, followed by L6 and MACE 10 ]. Details of drug doses and administration are shown in Table 1 . For the EBMT patients, details of the induction chemotherapy were not available.
Conditioning for the ABMT patients consisted of melphalan 140 mg/m 2 and total body irradiation (TBI) to 10.5 Gy in a single fraction. 13 For PBSCT patients, 34 received TBI containing regimes (90% fractionated) while 80 received non-TBI based regimens for conditioning. The ABMTs were carried out between 1990 and 2000 (28 (49%) before 1996), whereas all PBSCT procedures were undertaken after 1996.
Statistical analysis
Observations between the two groups of patients were compared according to the Kruskall-Wallis analysis of variance by rank.
14 Analysis of the influence of source of stem cells on relapse-free and overall survival was carried out according to the Kaplan-Meier method and the logrank test.
15,16
Results
Patients/matched-controls Table 2 shows the demography of the ABMT vs the PBSCT group. The karyotype matching between the two groups was perfect. Of the 57 ABMT patients, 22 had good risk disease, 17 intermediate risk, five poor risk and 13 were matched for FAB type as karyotype was not available. Table 3 depicts the karyotype data in the two groups. The median time intervals from attaining complete remission to autografting were comparable. As age was the fourth in the matching order, this was not perfectly matched. Patients in the ABMT group were significantly older (AML 3 ¼ 0.04). The presenting peripheral WBC was higher in the PBSCT than in the ABMT group (P ¼ 0.023).
Treatment/transplant details
No cytokines were used after ABMT, whereas at least 25% of PBSCT patients received growth factors. The median total nucleated cell counts transplanted in the ABMT and PBSCT groups were 2.6 and 9.0 Â 10 8 /kg respectively (Po0.0001).
Engraftment
The median time to neutrophil recovery to more than 0.5 Â 10 9 /l was more than twice as fast in the PBSCT group than among ABMT patients (13.5 days (3-54) vs 33 days /l, 18 days (1-1257) vs 36 days (9-161), P ¼ 0.002). Thus, 97% of the PBSCT patients had recovered neutrophils to 0.5 Â 10 9 /l by day 50 compared with 81% ABMT patients (P ¼ 0.0006) and 79% of the PBSCT patients had recovered platelets to 50 Â 10 9 /l by day 100 compared with 44% ABMT patients (Po0.0001).
Treatment-related mortality
One PBSCT patient and seven ABMT patients died of toxicity (HR 0.15, 95% CI 0.04-0.42, Figure 1a) , corresponding to a nonrelapse mortality (NRM) at 4 years of 1 vs 13% (P ¼ 0.037). In total, 35 patients in the ABMT group received a total nucleated cell dose of o3 Â 10 8 cells/ kg body weight and six of the seven patients who died were in this group.
Relapse and survival
Disease relapse occurred in 11/114 (10%) PBSCT patients and 14/57 (24%) ABMT patients (HR 0.69, 95% CI 0.32-1.23) and the relapse rate at 4 years was 20 and 31%, respectively (P ¼ 0.35, Figure 1b) . The 4-year overall survival figures were 77% for the PBSCT group and 63% in the ABMT group (P ¼ 0.15, Figure 1c ). At the last follow-up, 102 PBSCT patients (89%) were alive and well at 1-70 months after their autograph, compared to 36 ABMT patients (63%) at 2-132 months. (c) overall survival in 57 patients with AML in first complete remission who received an ABMT compared with 114 matched controls from the EBMT registry whose AML was consolidated using peripheral blood stem cells. ABMT vs PBSCT for AML in CR1 B Sirohi et al
Discussion
In AML, autotransplantation has been used in patients in CR as consolidation therapy in many studies, [1] [2] [3] 6, 9, 13, [17] [18] [19] [20] but this is not universally used as consolidation treatment in first remission because, in the two recent, large pivotal randomised trials though there was an improvement for disease-free survival, this did not translate into worthwhile improvement in overall survival. However, in the MRC AML10 study, the autograft arm was associated with a lower relapse rate in all risk groups -good, intermediate and poor, and the results were similar in the US study.
2,3
The reasons for not seeing better survival in both studies was because of transplant-related death rates of 12-14% compared with less than 1% for other forms of consolidation. Both these studies used ABMT, comparing it with other treatment options, both were large with one involving 163 centres in the UK and the other a quango of three major US multicentre leukaemia study groups, the Eastern Cooperative Oncology Group (ECOG), the South West Oncology Group (SWOG) and the Cancer and Leukaemia Group B (CALGB). The UK Study recruited 1966 patients and the US study 808 patients, and each study lasted over 5 years. It was therefore disappointing that low numbers of patients ended up receiving autografts; in the MRC study, 509 CR patients were recruited, 190 were randomised to receive autografting but finally only 126 actually received the treatment. The situation was similar in the US study: 518 went into CR, 116 were assigned to autograft, but only 63 received the treatment. Therefore only 6% and 8% of the new patients recruited into the trial received this treatment. In a letter to the New England Journal of Medicine, 21 it was felt that the 18% of patients who withdrew from the US study after randomisation to the autograft arm, compared with 4% in Cytarabine group and 3% in the allograft group, raised the question of a bias of the participating physicians against ABMT, but it was understandable at that time when ABMT carried the risk of one in eight patients dying because of the treatment. However, it is possible the best risk patients were the ones denied this treatment because it might naturally have been perceived that these would have been the ones with most to lose and may have been the same group that would have gained most benefit. They were, of course, included in the analysis on an intent to treat basis, but denied the treatment.
However, if the treatment could be made significantly safer this would change things; there is now much published data to show that if blood rather than marrow is used as the source of stem cells then the procedure is faster, safer, cheaper and not associated with increased relapse in a variety of settings, including lymphomas, acute lymphoblastic leukaemia and myeloma, [22] [23] [24] and autologous PBSC (rather than BM) transplants have now become standard treatment for consolidating myeloma.
The vastly improved safety of PBSC (TRM less than 3%), means that in many places it is done as an outpatient procedure. 25 This present study with the PBSC mortality of 1% may mean the perception on the part of the physicians passed on consciously or unconsciously to the patients may now be the opposite of that in the two pivotal studies with significant recruitment of all eligible patients.
Our results show that PBSCT is not associated with a higher risk of relapse after autografting for AML, which is in keeping with early (abstract) reports by de Witte et al, 9, 26 including a randomised trial of PBSCT vs ABMT. Though the relapse rate in the de Witte randomised study is not statistically significant (Table 4) , it is high at 54.4% with PBSCT compared to 45.3% with ABMT. Our data show that the relapse rate is lower with PBSCT (19.6%) compared to ABMT (31.1%), though our study is not powered to detect a difference in relapse and the two patient groups were not entirely comparable. The relapse rate in our matched-pair control study is much lower compared to the de Witte randomised study possibly due to a higher proportion of patients with good-risk disease (39% in ABMT and 35% in PBSCT) or the differences in the induction and consolidation regimens. Detailed data on the de Witte study is not available. A longer follow-up on the de Witte study is needed to make meaningful analysis possible.
The considerably lower TRM with PBSCT is likely to be due to the faster haemopoietic recovery associated with the higher number of haemopoietic cells infused with PBSCT. We have previously shown that the TRM after ABMT in AML is higher with low TNC doses. 13 Six of the seven deaths in the ABMT group occurred in the 35 patients who had received o3 Â 10 8 TNC/kg body weight. The higher deaths in CR in the ABMT group in our study compared to the de Witte study (12 vs 5%) is probably related to the lower infused TNC doses and the fact that almost 50% of the ABMT patients in our study were autografted before 1996.
In this present study, all ABMT patients received single fraction TBI compared to only 30% PBSCT patients receiving it; randomised studies comparing fractionated or hyperfractionated TBI to single fraction TBI have shown either better 27, 28 or comparable 29 survival. Concerning the issue of optimising the consolidation before autografting we have seen in myeloma, this is important with the best benefit being seen after attaining maximum response first with consolidative chemotherapy. 30 In our study presented here we feel that the induction and consolidation chemotherapy that the ABMT patients received prior to autografting will have been at least as intensive as the regimens used for the PBSCT patients, the difference in the outcome between the two groups is probably entirely attributable to the source of stem cells. Also, all the PBSCT patients have had the possible advantage of better supportive therapy (all after 1996) and younger age compared to the ABMT patients.
The design of a future AML study to test the efficacy of PBSC in the autotransplant setting may now be different from previous studies. In a series of 108 patients treated at a single institution over 20 years it has been shown that autologous stem cell transplantation should be part of a global treatment approach, a change in the whole strategy after 1989 (high-dose anthracycline in induction, addition of a second consolidation course) has resulted in an increase in CR rate (90 vs 77%), a better compliance to autografting (76 vs 48%) and a better disease-free survival rate (48 vs 32%; P ¼ 0.04). 31 Some previous studies have been concerned about being able to obtain sufficient stem cells when harvesting marrow after intensive chemotherapy because up to 20% of patients may require platelet support for months after transplant. 13 Hence, the MRC study harvested stem cells before the last consolidation in spite of this inevitably increasing the risk of tainting with residual leukaemia cells. 3 However the increased robustness of PBSC mitigates this problem.
We feel this present study makes a valid case for why high-dose consolidation with autografting rescue should again be assessed formally in a randomised trial setting, using PBSC as the source of stem cells, with adequate consolidation, perhaps without TBI and such a study might help clarify the conflicting statements that still pop up that autografting is recognised as a routine treatment modality for AML patients in first CR 20 in the face of current national trials not including it as a variable.
